SCHEMBL2272040

SCHEMBL2272040

COc1cccc(Oc2ccc(C(=O)O)c(NC(=O)c3ccccc3)c2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.69
PYGM P11217 2/20 0.67
KCNK2 O95069 1/20 0.61
KCNK10 P57789 1/20 0.61
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
PKM P14618 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58
NLRP3 Q96P20 1/20 0.58
AKR1C3 P42330 3/20 0.57
AKR1C2 P52895 3/20 0.57
PPARG P37231 1/20 0.57
PPARD Q03181 1/20 0.57
GPBAR1 Q8TDU6 1/20 0.57
NR1H4 Q96RI1 1/20 0.57
MAPT P10636 1/20 0.56
KCNK3 O14649 1/20 0.55
KCNK9 Q9NPC2 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2271177 0.94 PYGM (0.72) PGRPYGMMEN1KMT2ANPC1
SCHEMBL2272706 0.92 MEN1 (0.67) PGRPYGMKCNK2KCNK10MEN1
SCHEMBL2935687 0.92 MEN1 (0.69) PYGMKCNK2KCNK10MEN1KMT2A
SCHEMBL2271007 0.91 MEN1 (0.69) PGRPYGMKCNK2KCNK10MEN1
SCHEMBL14428488 0.90 PGR (0.66) PGRPYGMMEN1KMT2ANPC1
SCHEMBL2271588 0.90 SERPINE1 (0.64) PGRPYGMMEN1KMT2APKM
SCHEMBL2293458 0.89 PGR (0.67) PGRPYGMMEN1KMT2APKM
SCHEMBL2273166 0.88 GFER (0.61) PYGMMEN1KMT2APKMNR1H4
SCHEMBL2274026 0.86 PGR (0.61) PGRPYGMKCNK2KCNK10MEN1
SCHEMBL2271920 0.86 SERPINE1 (0.57) PYGMMEN1KMT2APKMAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 PGR 3411/4885PYGM 1299/4885KCNK2 3527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.